Results 111 to 120 of about 2,341,438 (252)

Discovery and Optimization of AMT‐676, a CDH17‐Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers

open access: yesAdvanced Science, EarlyView.
AMT‐676 is a novel antibody‐drug conjugate targeting CDH17, an adhesion molecule uniquely exposed on gastrointestinal tumor surfaces. Engineered with an optimized exatecan payload, it demonstrates profound tumor regression and a robust bystander effect across diverse preclinical models.
Ying‐nan Wang   +21 more
wiley   +1 more source

Targeted Therapies for Driver Gene Mutation-positive Lung Cancer Patients with Brain Metastasis

open access: yesChinese Journal of Lung Cancer, 2019
Brain is the most common site of lung cancer metastasis, and the incidenceis are higher if patients have driver gene mutation. Patients with brain metastasis have a poor prognosis; further, different treatment methods affect the disease status and ...
Wenqian LI, Rilan BAI, Jiuwei CUI
doaj   +1 more source

MicroRNAs in Lung Cancer Brain Metastasis

open access: yes
Brain metastasis is a significant clinical challenge for patients with advanced lung cancer, occurring in about 20–40% of cases. Brain metastasis causes severe neurological symptoms, leading to a poor prognosis and contributing significantly to ...
Blanca Ortiz-Quintero   +2 more
core   +1 more source

Targeting LDHA Palmitoylation Sensitizes GBM to Chemoradiotherapy via Suppressing Palmitic Acid Induced Glycolytic Reprogramming

open access: yesAdvanced Science, EarlyView.
Mesenchymal GSCs preferentially uptake palmitic acid, thereby promoting ZDHHC12‐mediated LDHA palmitoylation. This modification enhances LDHA enzymatic activity, drives glycolytic reprogramming, and facilitates exosomal LDHA‐mediated TAM regulation.
Zijie Gao   +20 more
wiley   +1 more source

A bar chart of relative frequency of each visual grade in GBM and brain metastasis.

open access: yes, 2016
GBM occupies a larger proportion of grade 5 tumors than brain metastasis, whereas brain metastasis occupies a larger proportion of grade 1 tumors than GBM.
Seung Hong Choi (107291)   +10 more
core   +1 more source

Dual‐Target Nectin‐4/FAP Heterobivalent Probe 68Ga/177Lu‐FZ‐NF‐1 for Triple‐Negative Breast Cancer: Preclinical Theranostic Evaluation and First‐in‐Human Translation

open access: yesAdvanced Science, EarlyView.
A novel hetero‐bivalent agent, 68Ga/177Lu‐FZ‐NF‐1, concurrently targets Nectin‐4 and FAP in triple‐negative breast cancer. It yields significant preclinical tumor regression and clinically identifies additional metastatic lesions missed by 18F‐FDG PET, demonstrating promising theranostic potential for personalized management.
Ye Li   +13 more
wiley   +1 more source

Spatial Transcriptomics Reveals a T Cell‐Mediated Microglial Activation Axis of Immune Checkpoint Inhibition‐Related Adverse Events in the Brain

open access: yesAdvanced Science, EarlyView.
Immune checkpoint inhibition (ICI) reshapes the hippocampal neuroimmune niche. Spatial transcriptomic profiling and human brain histological analyses identify neuroinflammation and altered neuronal and glial programs. Notably, T cell depletion prevents ICI‐driven microglial activation, establishing the T cell–microglia crosstalk axis as a driving ...
Devyani Swami   +7 more
wiley   +1 more source

Smart Bioinks for 4D Bioprinting: Requirements, Design, and Applications

open access: yesAdvanced Science, EarlyView.
Smart bioinks empower 4D‐bioprinted constructs to dynamically adapt and remodel in response to stimuli, effectively biomimicking native tissues. Artificial Intelligence (AI) and Machine Learning (ML) play a guiding role in their rational design by optimizing relevant properties.
Shangsi Chen   +11 more
wiley   +1 more source

Epigenetic Silencing of CYYR1 Promotes Lung Adenocarcinoma Progression Through TRIM21‐Dependent Regulation of HMMR Stability

open access: yesAdvanced Science, EarlyView.
CYYR1 as an epigenetically dysregulated tumor‐suppressive factor that influences oncoprotein stability through TRIM21‐dependent HMMR regulation and reveals a potential therapeutic vulnerability in CYYR1‐deficient LUAD. The graphical illustration was created using FigDraw (www.figdraw.com).
Fengsheng Dai   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy